Tirzepatide denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Tirzepatide as Duplicate Therapy

Aetna's duplicate-therapy denial means the plan's system flagged that you are currently receiving — or recently received — another medication it considers therapeutically equivalent to tirzepatide. This most commonly occurs when a GLP-1 receptor agonist or another glucose-lowering or weight-management agent is still active on your pharmacy record, even if you and your prescriber intend tirzepatide to replace it entirely.

This denial is worth appealing because tirzepatide has a distinct mechanism of action from other agents in the broader class, and your prescriber can document the specific clinical rationale for why switching — rather than continuing the existing therapy — is medically necessary for your individual case.

## Your Appeal Rights

Federal law gives you a structured path to challenge this denial:

• ACA §2719 / ERISA §503: Non-grandfathered group health plans and individual-market ACA plans must provide a full-and-fair internal review followed by access to independent external review.
• Internal appeal deadline: Typically 180 days from the denial notice — check your Explanation of Benefits for the exact date.
• External review window: If the internal appeal is denied, you generally have four months from that denial to request independent external review.
• Expedited option: If your condition is urgent, you may request an expedited internal and/or external review, which must be decided within shorter timeframes defined by federal regulation.

## Documentation to Gather

1. Discontinuation or transition record: Written evidence — including the date — that the prior overlapping therapy is being stopped or was already stopped, with the prescriber's rationale. 2. Diagnosis confirmation: Current chart documentation of your diagnosis (e.g., type 2 diabetes, obesity, or both) with severity and relevant comorbidities. 3. Treatment history with dates and outcomes: A chronological list of every prior agent tried, the duration of each trial, and the clinical outcome (inadequate glycemic control, intolerable side effects, contraindication per the treating clinician's judgment). 4. Medical-necessity letter: A detailed letter from your prescriber explaining why tirzepatide is not duplicative — specifically, how its mechanism or clinical profile addresses a need the prior agent did not, and why the prior therapy is no longer appropriate. 5. Insurer policy mapping: Obtain Aetna's current published clinical policy for tirzepatide. Copy each criterion listed and document, line by line, exactly how your chart satisfies it.

## Criteria-Mapping Structure

Organize your appeal around a table with three columns: Aetna's stated requirement (copied verbatim from the policy) | Supporting document and page | Exact chart fact that satisfies it. Pay particular attention to any policy language addressing concurrent or recent use of other agents, and address it directly. Your prescriber's letter should mirror this structure.

Confirm the current approved indication, dosing, and eligibility criteria against the FDA-approved prescribing information for tirzepatide and against Aetna's most recently published coverage policy before submitting — both documents may have been updated since your prescription was written.